Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Three-component metal-free arylation of isocyanides.
Basavanag UM, Dos Santos A, El Kaim L, Gámez-Montaño R, Grimaud L. Basavanag UM, et al. Among authors: dos santos a. Angew Chem Int Ed Engl. 2013 Jul 8;52(28):7194-7. doi: 10.1002/anie.201302659. Epub 2013 May 29. Angew Chem Int Ed Engl. 2013. PMID: 23720396 No abstract available.
Unconventional oxazole formation from isocyanides.
dos Santos A, El Kaïm L, Grimaud L, Ronsseray C. dos Santos A, et al. Chem Commun (Camb). 2009 Jul 14;(26):3907-9. doi: 10.1039/b904699b. Epub 2009 May 20. Chem Commun (Camb). 2009. PMID: 19662248
Double Smiles rearrangement of Passerini adducts towards benzoxazinones.
Martinand-Lurin E, Dos Santos A, El Kaim L, Grimaud L, Retailleau P. Martinand-Lurin E, et al. Among authors: dos santos a. Chem Commun (Camb). 2014 Feb 28;50(17):2214-7. doi: 10.1039/c3cc49022j. Epub 2014 Jan 17. Chem Commun (Camb). 2014. PMID: 24435182
Formal [3+2] cycloaddition of Ugi adducts towards pyrrolines.
Ben Abdessalem A, Abderrahim R, Agrebie A, Dos Santos A, El Kaïm L, Khomenko A. Ben Abdessalem A, et al. Among authors: dos santos a. Chem Commun (Camb). 2015 Jan 21;51(6):1116-9. doi: 10.1039/c4cc08282f. Chem Commun (Camb). 2015. PMID: 25461834
Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
Coutts SB, Ankolekar S, Appireddy R, Arenillas JF, Assis Z, Bailey P, Barber PA, Bazan R, Buck BH, Butcher KS, Camden MC, Campbell B, Casaubon LK, Catanese L, Chatterjee K, Choi PMC, Clarke B, Dowlatshahi D, Ferrari J, Field TS, Ganesh A, Ghia D, Goyal M, Greisenegger S, Halse O, Horn M, Hunter G, Imoukhuede O, Kelly PJ, Kennedy J, Kenney C, Kleinig TJ, Krishnan K, Lima F, Mandzia JL, Marko M, Martins SO, Medvedev G, Menon BK, Mishra SM, Molina C, Moussaddy A, Muir KW, Parsons MW, Penn AMW, Pille A, Pontes-Neto OM, Roffe C, Serena J, Simister R, Singh N, Spratt N, Strbian D, Tham CH, Wiggam MI, Williams DJ, Willmot MR, Wu T, Yu AYX, Zachariah G, Zafar A, Zerna C, Hill MD; TEMPO-2 investigators. Coutts SB, et al. Lancet. 2024 May 16:S0140-6736(24)00921-8. doi: 10.1016/S0140-6736(24)00921-8. Online ahead of print. Lancet. 2024. PMID: 38768626
2,362 results